Treatments | Concentrations (g/l) | Percent mortality | |||
---|---|---|---|---|---|
Days of observation | |||||
3rd | 5th | 7th | 10th | ||
M. rileyi NIPHM | 8 | 8.33cba (16.59) | 16.67ba (24.03) | 21.67dcb (27.51) | 33.33dc (35.20) |
10 | 10.00cba (18.42) | 23.33a (28.77) | 33.33cba (35.15) | 45.00cba (42.10) | |
12 | 16.67a (23.84) | 30.00a (33.02) | 45.00a (42.10) | 63.33a (52.77) | |
M. rileyi MTCC 4254 | 8 | 6.67cba (12.28) | 15.00ba (22.58) | 21.67dcb (27.58) | 30.00dc (32.98) |
10 | 8.33cba (16.59) | 21.67ba (27.02) | 28.33cba (31.73) | 40.00dcb (39.13) | |
12 | 13.33ba (21.13) | 26.67a (31.05) | 38.33ba (38.17) | 58.33ba (48.81) | |
M. rileyi MTCC 10395 | 8 | 3.33cb (6.14) | 13.33ba (21.32) | 16.67dc (23.84) | 23.33ed (28.77) |
10 | 6.67cba (12.28) | 18.33ba (24.98) | 25.00dcba (29.91) | 36.67dc (37.24) | |
12 | 10.00cba (18.04) | 26.67a (30.98) | 33.33cba (35.20) | 43.33cb (41.14) | |
Control | 0.00c (0.00) | 5.00b (10.44) | 6.67d (12.28) | 10.00e (18.42) | |
*CD (5%) | (11.14) | (8.96) | (9.69) | (6.89) |